Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 302

1.

Wheat Consumption Aggravates Colitis in Mice via Amylase Trypsin Inhibitor-mediated Dysbiosis.

Pickert G, Wirtz S, Matzner J, Ashfaq-Khan M, Heck R, Rosigkeit S, Thies D, Surabattula R, Ehmann D, Wehkamp J, Aslam M, He G, Weigert A, Foerster F, Klotz L, Frick JS, Becker C, Bockamp E, Schuppan D.

Gastroenterology. 2020 Apr 3. pii: S0016-5085(20)30447-9. doi: 10.1053/j.gastro.2020.03.064. [Epub ahead of print]

PMID:
32251667
2.

Lysyl oxidase (LOX) family members: rationale and their potential as therapeutic targets for liver fibrosis.

Chen W, Yang A, Jia J, Popov YV, Schuppan D, You H.

Hepatology. 2020 Mar 16. doi: 10.1002/hep.31236. [Epub ahead of print] Review.

PMID:
32176358
3.

β-arrestin: Dr Jekyll and Mr Hyde in NASH and fibrosis.

Abe H, Schuppan D.

J Hepatol. 2020 Feb 28. pii: S0168-8278(20)30057-X. doi: 10.1016/j.jhep.2020.01.016. [Epub ahead of print] No abstract available.

PMID:
32122723
4.

Collagen biology and non-invasive biomarkers of liver fibrosis.

Karsdal MA, Daniels SJ, Holm Nielsen S, Bager C, Rasmussen DGK, Loomba R, Surabattula R, Villesen IF, Luo Y, Shevell D, Gudmann NS, Nielsen MJ, George J, Christian R, Leeming DJ, Schuppan D.

Liver Int. 2020 Jan 29. doi: 10.1111/liv.14390. [Epub ahead of print] Review.

PMID:
31997561
5.

TGF-β2 silencing to target biliary-derived liver diseases.

Dropmann A, Dooley S, Dewidar B, Hammad S, Dediulia T, Werle J, Hartwig V, Ghafoory S, Woelfl S, Korhonen H, Janicot M, Wosikowski K, Itzel T, Teufel A, Schuppan D, Stojanovic A, Cerwenka A, Nittka S, Piiper A, Gaiser T, Beraza N, Milkiewicz M, Milkiewicz P, Brain JG, Jones DEJ, Weiss TS, Zanger UM, Ebert M, Meindl-Beinker NM.

Gut. 2020 Jan 28. pii: gutjnl-2019-319091. doi: 10.1136/gutjnl-2019-319091. [Epub ahead of print]

6.

Investigating fibrosis and inflammation in an ex vivo NASH murine model.

Gore E, Bigaeva E, Oldenburger A, Jansen YJM, Schuppan D, Boersema M, Rippmann JF, Broermann A, Olinga P.

Am J Physiol Gastrointest Liver Physiol. 2020 Feb 1;318(2):G336-G351. doi: 10.1152/ajpgi.00209.2019. Epub 2020 Jan 6.

PMID:
31905025
7.

A randomized, placebo-controlled trial of emricasan in patients with NASH and F1-F3 fibrosis.

Harrison SA, Goodman Z, Jabbar A, Vemulapalli R, Younes ZH, Freilich B, Sheikh MY, Schattenberg JM, Kayali Z, Zivony A, Sheikh A, Garcia-Samaniego J, Satapathy SK, Therapondos G, Mena E, Schuppan D, Robinson J, Chan JL, Hagerty DT, Sanyal AJ.

J Hepatol. 2019 Dec 27. pii: S0168-8278(19)30758-5. doi: 10.1016/j.jhep.2019.11.024. [Epub ahead of print]

PMID:
31887369
8.

The enemy within the gut: bacterial pathogens in celiac autoimmunity.

Verdu EF, Schuppan D.

Nat Struct Mol Biol. 2020 Jan;27(1):5-7. doi: 10.1038/s41594-019-0360-5. No abstract available.

PMID:
31873302
9.

Dietary wheat amylase trypsin inhibitors promote features of murine non-alcoholic fatty liver disease.

Ashfaq-Khan M, Aslam M, Qureshi MA, Senkowski MS, Yen-Weng S, Strand S, Kim YO, Pickert G, Schattenberg JM, Schuppan D.

Sci Rep. 2019 Nov 25;9(1):17463. doi: 10.1038/s41598-019-53323-x.

10.

Endothelial GLP-1 (Glucagon-Like Peptide-1) Receptor Mediates Cardiovascular Protection by Liraglutide In Mice With Experimental Arterial Hypertension.

Helmstädter J, Frenis K, Filippou K, Grill A, Dib M, Kalinovic S, Pawelke F, Kus K, Kröller-Schön S, Oelze M, Chlopicki S, Schuppan D, Wenzel P, Ruf W, Drucker DJ, Münzel T, Daiber A, Steven S.

Arterioscler Thromb Vasc Biol. 2020 Jan;40(1):145-158. doi: 10.1161/atv.0000615456.97862.30. Epub 2019 Nov 21.

11.

Exploring organ-specific features of fibrogenesis using murine precision-cut tissue slices.

Bigaeva E, Gore E, Mutsaers HAM, Oosterhuis D, Kim YO, Schuppan D, Bank RA, Boersema M, Olinga P.

Biochim Biophys Acta Mol Basis Dis. 2020 Jan 1;1866(1):165582. doi: 10.1016/j.bbadis.2019.165582. Epub 2019 Oct 30.

12.

Comparison of murine steatohepatitis models identifies a dietary intervention with robust fibrosis, ductular reaction, and rapid progression to cirrhosis and cancer.

Wei G, An P, Vaid KA, Nasser I, Huang P, Tan L, Zhao S, Schuppan D, Popov YV.

Am J Physiol Gastrointest Liver Physiol. 2020 Jan 1;318(1):G174-G188. doi: 10.1152/ajpgi.00041.2019. Epub 2019 Oct 21.

13.

Serum markers of type III and IV procollagen processing predict recurrence of fibrosis in liver transplanted patients.

Nielsen MJ, Villesen IF, Gudmann NS, Leeming DJ, Krag A, Karsdal MA, Zimmermann T, Schuppan D.

Sci Rep. 2019 Oct 16;9(1):14857. doi: 10.1038/s41598-019-51394-4.

14.

Is the Total Amount as Important as Localization and Type of Collagen in Liver Fibrosis Attributable to Steatohepatitis?

Karsdal MA, Detlefsen S, Daniels SJ, Nielsen MJ, Krag A, Schuppan D.

Hepatology. 2020 Jan;71(1):346-351. doi: 10.1002/hep.30969. Epub 2019 Dec 18. Review. No abstract available.

PMID:
31553813
15.

PI3K inhibition reduces murine and human liver fibrogenesis in precision-cut liver slices.

Gore E, Bigaeva E, Oldenburger A, Kim YO, Rippmann JF, Schuppan D, Boersema M, Olinga P.

Biochem Pharmacol. 2019 Nov;169:113633. doi: 10.1016/j.bcp.2019.113633. Epub 2019 Sep 5.

16.

Deletion of organic cation transporter Oct3 promotes hepatic fibrosis via upregulation of TGFβ.

Vollmar J, Kim YO, Marquardt JU, Becker D, Galle PR, Schuppan D, Zimmermann T.

Am J Physiol Gastrointest Liver Physiol. 2019 Aug 1;317(2):G195-G202. doi: 10.1152/ajpgi.00088.2019. Epub 2019 Jun 26.

PMID:
31241979
17.

α-Mannosyl-Functionalized Cationic Nanohydrogel Particles for Targeted Gene Knockdown in Immunosuppressive Macrophages.

Leber N, Kaps L, Yang A, Aslam M, Giardino M, Klefenz A, Choteschovsky N, Rosigkeit S, Mostafa A, Nuhn L, Schuppan D, Zentel R.

Macromol Biosci. 2019 Jul;19(7):e1900162. doi: 10.1002/mabi.201900162. Epub 2019 Jun 7.

PMID:
31173461
18.

Many Patients With Irritable Bowel Syndrome Have Atypical Food Allergies Not Associated With Immunoglobulin E.

Fritscher-Ravens A, Pflaum T, Mösinger M, Ruchay Z, Röcken C, Milla PJ, Das M, Böttner M, Wedel T, Schuppan D.

Gastroenterology. 2019 Jul;157(1):109-118.e5. doi: 10.1053/j.gastro.2019.03.046. Epub 2019 May 15.

PMID:
31100380
19.

Pharmaceutically modified subtilisins withstand acidic conditions and effectively degrade gluten in vivo.

Darwish G, Helmerhorst EJ, Schuppan D, Oppenheim FG, Wei G.

Sci Rep. 2019 May 16;9(1):7505. doi: 10.1038/s41598-019-43837-9.

20.

Clinical Guide and Update on Porphyrias.

Stölzel U, Doss MO, Schuppan D.

Gastroenterology. 2019 Aug;157(2):365-381.e4. doi: 10.1053/j.gastro.2019.04.050. Epub 2019 May 11. Review.

PMID:
31085196

Supplemental Content

Loading ...
Support Center